Caribou Biosciences (CRBU) vs OKYO Pharma (OKYO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
OKYO Pharma (OKYO) has outperformed Caribou Biosciences (CRBU) over the past year, losing 37.9% versus a loss of 82.0%. OKYO Pharma is the larger company by market cap ($72.9 million vs $51.6 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBU | OKYO |
|---|---|---|
| Share price | $0.4812 | $1.39 |
| Market cap | $51.59M | $72.95M |
| 1-day change | -22.06% | -2.73% |
| YTD return | -69.74% | -32.85% |
| 1-year return | -82.04% | -37.95% |
| 5-year return | -97.69% | — |
| EPS (TTM) | $-1.08 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.54 | $3.20 |
| 52-week low | $0.45 | $1.27 |
| Distance from 52-week high | -86.39% | -56.56% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +1094.93% | +499.28% |
| Average volume | 2.14M | 94.59K |
| Shares outstanding | 107.21M | 52.48M |
| Employees | 97 | 5 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OKYO has outperformed CRBU by 44.1 percentage points over the past year.
About Caribou Biosciences
CRBU stock →Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company.
Healthcare · Biotechnology · 97 employees
About OKYO Pharma
OKYO stock →OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.
Healthcare · Biotechnology · 5 employees
CRBU vs OKYO FAQ
Which is bigger, Caribou Biosciences or OKYO Pharma?
OKYO Pharma (OKYO) is larger, with a market capitalization of $72.95M compared with $51.59M for Caribou Biosciences (CRBU).
Which stock has performed better over the past year, CRBU or OKYO?
OKYO returned -37.95% over the past 12 months, compared with -82.04% for CRBU (price return, excluding dividends). Past performance does not predict future results.
Are Caribou Biosciences and OKYO Pharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.